{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:39:15Z","timestamp":1781195955377,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1245\/s10434-015-4991-4","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T12:18:44Z","timestamp":1448972324000},"page":"1294-1301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis"],"prefix":"10.1245","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-5582","authenticated-orcid":false,"given":"Glauco","family":"Baiocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Oliveira","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Mantoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Andre Balieiro Anastacio","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Chaves","family":"Faloppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian Yuri","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso Abdon Lopes","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Mayumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Toshihiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Samuel","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ademar","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"4991_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u02bcInvestigateurs Nationaux Pour les Etudes des Cancers de l\u02bcOvaire (GINECO). Cancer. 2009;115:1234\u201344.","journal-title":"Cancer."},{"key":"4991_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated withintraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2015;33:1460\u20136.","journal-title":"J Clin Oncol."},{"key":"4991_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","volume":"20","author":"JA Lopez","year":"1985","unstructured":"Lopez JA, Krikorian JG, Reich SD, et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20:1\u20139.","journal-title":"Gynecol Oncol."},{"key":"4991_CR4","first-page":"1085","volume":"67","author":"RG Pretorius","year":"1983","unstructured":"Pretorius RG, Hacker NF, Berek JS, et al. Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085\u201392.","journal-title":"Cancer Treat Rep."},{"key":"4991_CR5","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 1995;13:2961\u20137.","journal-title":"J Clin Oncol."},{"key":"4991_CR6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485\u201391.","journal-title":"J Clin Oncol."},{"key":"4991_CR7","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita Jr, VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep."},{"key":"4991_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med."},{"key":"4991_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:27\u201332.","journal-title":"Gynecol Oncol."},{"key":"4991_CR10","doi-asserted-by":"crossref","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:CD008765.","DOI":"10.1002\/14651858.CD008765.pub3"},{"key":"4991_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cncr.23553","volume":"113","author":"A Giorgio Di","year":"2008","unstructured":"Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315\u201325.","journal-title":"Cancer."},{"key":"4991_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ejso.2009.03.004","volume":"35","author":"MJ Pavlov","year":"2009","unstructured":"Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer\u201412-year single center experience. Eur J Surg Oncol. 2009;35:1186\u201391.","journal-title":"Eur J Surg Oncol."},{"key":"4991_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/IGC.0b013e3181c50cde","volume":"20","author":"CW Helm","year":"2010","unstructured":"Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20:61\u20139.","journal-title":"Int J Gynecol Cancer."},{"key":"4991_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jso.21682","volume":"102","author":"F Roviello","year":"2010","unstructured":"Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol. 2010;102:663\u201370.","journal-title":"J Surg Oncol."},{"key":"4991_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.amjsurg.2011.02.004","volume":"202","author":"EN Parson","year":"2011","unstructured":"Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011;202:481\u20136.","journal-title":"Am J Surg."},{"key":"4991_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","volume":"122","author":"M Deraco","year":"2011","unstructured":"Deraco M, Kusamura S, Virz\u00ec S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122:215\u201320.","journal-title":"Gynecol Oncol."},{"key":"4991_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, et al; FROGHI (FRench Oncologic and Gynecologic HIPEC) Group. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435\u201343.","journal-title":"Eur J Surg Oncol."},{"key":"4991_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","volume":"136","author":"LM Chiva","year":"2015","unstructured":"Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136:130\u20135.","journal-title":"Gynecol Oncol."},{"key":"4991_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637\u201345.","journal-title":"J Cancer Res Clin Oncol."},{"key":"4991_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jviscsurg.2014.07.005","volume":"151","author":"N Bakrin","year":"2014","unstructured":"Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg. 2014;151:347\u201353.","journal-title":"J Visc Surg."},{"key":"4991_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","volume":"11","author":"FC Munoz-Casares","year":"2009","unstructured":"Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753\u20139.","journal-title":"Clin Transl Oncol."},{"key":"4991_CR22","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol. 2012;127:502\u20135.","journal-title":"Gynecol Oncol."},{"key":"4991_CR23","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","volume":"21","author":"J Brun Le","year":"2014","unstructured":"Le Brun J, Campion L, Berton-Rigaud D, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case-control study. Ann Surg Oncol. 2014;21:3621\u20137.","journal-title":"Ann Surg Oncol."},{"key":"4991_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/jso.23688","volume":"110","author":"T Safra","year":"2014","unstructured":"Safra T, Grisaru D, Inbar M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients\u2014a case-control study. J Surg Oncol. 2014;110:661\u20135.","journal-title":"J Surg Oncol."},{"key":"4991_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","volume":"6","author":"P Sugarbaker","year":"1999","unstructured":"Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727\u201331.","journal-title":"Ann Surg Oncol."},{"key":"4991_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","volume":"107","author":"GD Aletti","year":"2007","unstructured":"Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99\u2013106.","journal-title":"Gynecol Oncol."},{"key":"4991_CR27","first-page":"2264","volume":"73","author":"GM Hahn","year":"1979","unstructured":"Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979;73:2264\u20138.","journal-title":"Cancer Res."},{"key":"4991_CR28","first-page":"455","volume":"73","author":"DS Alberts","year":"1980","unstructured":"Alberts DS, Peng YM, Chen HS, et al. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Nat Cancer Inst. 1980;73:455\u201361.","journal-title":"J Nat Cancer Inst."},{"key":"4991_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00262768","volume":"21","author":"MJ Xu","year":"1988","unstructured":"Xu MJ, Alberts DS. Potentiation of platinum analogue cytotoxicity by hyperthermia. Cancer Chemother Pharmacol. 1988;21:191\u20136.","journal-title":"Cancer Chemother Pharmacol."},{"key":"4991_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/gyno.1994.1288","volume":"55","author":"R Maymon","year":"1994","unstructured":"Maymon R, Bar-Shira Maymon B, Holzinger M, Tartakovsky B, & Leibovici J. Augmentative effects of intracellular chemotherapy penetration combined with hyperthermia in human ovarian cancer cells lines. Gynecol Oncol. 1994;55:265\u201370.","journal-title":"Gynecol Oncol."},{"key":"4991_CR31","first-page":"56","volume":"30","author":"YP Istomin","year":"2008","unstructured":"Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, & Petrovich SV. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30:56\u20139.","journal-title":"Exp Oncol."},{"key":"4991_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570\u20135.","journal-title":"Ann Surg Oncol."},{"key":"4991_CR33","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol."},{"key":"4991_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588\u201391.","journal-title":"Br J Cancer."},{"key":"4991_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","volume":"132","author":"P Harter","year":"2014","unstructured":"Harter P, Beutel B, Alesina PF, et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132:537\u201341.","journal-title":"Gynecol Oncol."},{"key":"4991_CR36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890\u20136.","journal-title":"Br J Cancer."},{"key":"4991_CR37","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","volume":"20","author":"C Fotopoulou","year":"2013","unstructured":"Fotopoulou C, Zang R, Gultekin M, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol. 2013;20:1348\u201354.","journal-title":"Ann Surg Oncol."},{"key":"4991_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1245\/s10434-009-0787-8","volume":"17","author":"S Kommoss","year":"2010","unstructured":"Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 2010;17:279\u201386.","journal-title":"Ann Surg Oncol."},{"key":"4991_CR39","unstructured":"Morgan RJ Jr, Alvarez RD, Armstrong DK, et al; National Comprehensive Cancer Networks. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11:1199\u2013209."},{"key":"4991_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0032-1328320","volume":"73","author":"P Harter","year":"2013","unstructured":"Harter P, Mahner S, Hilpert F, et al. Statement by the Kommission OVAR of the AGO Study Group on the use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to treat primary and recurrent ovarian cancer. Geburtshilfe Frauenheilkd. 2013;73:221\u20133.","journal-title":"Geburtshilfe Frauenheilkd."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-015-4991-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4991-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T20:14:00Z","timestamp":1581970440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-015-4991-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["4991"],"URL":"https:\/\/doi.org\/10.1245\/s10434-015-4991-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]},"assertion":[{"value":"29 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2015","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}